News | January 11, 2010

SRS Reirradiation for Head-and-Neck Cancer Found Feasible

January 11, 2010 - Reirradiation using fractionated stereotactic radiosurgery (SRS) after previous radiotherapy for head-and-neck cancer is feasible, concluded researchers a study published in the Official Journal of the American Society for Radiation Oncology.

The researchers wanted to find the feasibility of stereotactic radiosurgery (SRS) because it “is an appealing treatment option after previous radiotherapy because of its precision, conformality, and reduced treatment duration.”

From 2002 to 2008, 65 patients received SRS to the oropharynx (13), hypopharynx (8), nasopharynx (7), paranasal sinus (7), neck (7), and other sites (23). Thirty-eight patients were treated definitively and 27 patients with metastatic disease and/or untreated local disease were treated palliatively. Nine patients underwent complete macroscopic resection before SRS. Thirty-three patients received concurrent chemoradiation. The median initial radiation dose was 67 Gy, and the median reirradiation SRS dose was 30 Gy (21–35 Gy) in 2–5 fractions.

Follow-up was on average 16 months for surviving patients. Fifty-six patients were evaluable for response: 30 (54 percent) had complete, 15 (27 percent) had partial, and 11 (20 percent) had no response. The overall survival (OS) for all patients averaged 12 months. For definitively treated patients, the 2-year OS and locoregional control (LRC) rates were 41 percent and 30 percent, respectively. Multivariate analysis demonstrated that higher total dose, surgical resection, and nasopharynx site were significantly associated with improved LRC; surgical resection and nonsquamous histology were associated with improved OS. Seven patients (11 percent) experienced severe reirradiation-related toxicity, including one treatment-attributed death.

Researchers concluded their findings showing SRS reirradiation for head-and-neck cancer a feasible demonstrated encouraging response rates with acceptable toxicity.

But they cautioned, “Fractionated SRS reirradiation with concurrent chemotherapy in select patients warrants further study.”

Reference: Unger, M.D., K.; Lominska, M.D., C.; Deeken, M.D., J.; et al. Fractionated Stereotactic Radiosurgery for Reirradiation of Head-and-Neck Cancer. doi:10.1016/j.ijrobp.2009.06.070

For more information: www.redjournal.org

Related Content

Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...
A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers. #ASTRO18 #ASTRO2018

A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers.

Feature | Proton Therapy | November 01, 2018 | Dave Fornell, Editor
A few of the big takeaways from the American Societ...